drugset
drugset / Trial / NCT04335604

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

NCT04335604 ↗

Phase 1 Completed 62 enrolled Onconic Therapeutics Inc. Jeil Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

Timeline

Start
2017-12-06
Primary completion
2021-12-14
Completion
2021-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesuparib Small molecule — —

Indications

cancer